Table 2.
Comparison of published case reports on the combination of DLI+TKI in T-ALL.
| Yoshimitsu et al. (15) | Tiribelli et al. (16) | Tachibana et al. (17) | Maharaj et al. (5) | |
| WBC (μl)/Hb (g/dl)/platelets (μl) at diagnosis | 11,700/10.2/28,000 | NA | 40,800/NA/NA | 67,000/12.3/49,000 |
| BM Blasts | 98.6% | NA | 97% | NA |
| Blasts phenotypes | CD10+, CD13+, CD19+, CD34+,CD33+ | NA | CD10+, CD13+, CD19+, CD34+, HLA-DR+ | NA |
| BCR-ABL isoform | p190 | p190 | NA | p190 |
| SNC involvement | NA | Meningeal and ocular | NA | NA |
| 1th Induction regimen | ALL202 (prednisolone, CPA, daunorubicin, VCR) + imatinib + intrathecal CHT (methotrexate, ARA-C and DEX) | VCR, daunorubicin, l-asparaginase and prednisone + intrathecal CHT (methotrexate, ARA-C and DEX) | Prednisolone, DXR, vindesine and CPA + imatinib | UKALL14 (PEG-asparaginase, daunorubicin, VCR, CPA, ARA-C, mercapopurine, DEX + + intrathecal CHT (methotrexate) |
| 1th consolidation regimen | HD MTX and HD ARA-C | HAM protocol (HD ARA-C and mitoxantrone) + CNS radiotherapy | MTX, ARA-C, and methylprednisolone | CPA + total body irradiation |
| Response to 1th treatment | CCR | CCR | CMR | CMR |
| CD34+ cell dose during transplant | 5.0 × 106/kg | 3.0 × 106/kg | NA | NA |
| Time from allo-SCT to first relapse (months) | 4.5 | 5.5 | 3.0 | 6 |
| Treatment after relapse | Imatinib ± DLI | Imatinib BFM protocol (VCR, ifosfamide, MTX, ARA-C, and teniposide) DLI + VCR + prednisone Nilotinib ± DLI | imatinib, CPA, DXR, VCR and prednisolone Imatinib ± DLI imatinib, CPA, DXR, VCR, and prednisolone Dasatinib | Dasatinib ± DLI Dasatinib + IL-2 |
| Best response to TKI + DLI | CMR | CMR | CCR maintenance | CCR |
| Signs of GVHD | ANA+ | grade I skin and liver GVHD | None | NA |
| Last reported status | CMR at 24 months after Imatinib + DLI start | CMR at 10 months after Nilotinib + DLI start | Relapse at 8 months after Imatinib + DLI start | Relapse at 6 months after Dasatinib + DLI start |
HD, high doses; MTX, methotrexate; ARA-C, cytarabine; VCR, vincristine; CPA, cyclophosophamide; DEX, dexamethasone; DXR, doxorubicin; DLI, donor lymphocytes infusion; CCR, complete cytogenetic remission, CMR, complete molecular remission; allo-SCT, allogenic stem cell transplant; NA, not available.